Form D · Biotechnology
STAGEZERO LIFE SCIENCES LTD.
Richmond Hill, A6 · CIK 0001454263
Offering snapshot reported Mar 17, 2022 · SEC filing
- Reported sold
- $1.48M Offering amount: $3.22M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 2, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2022 | Initial | $1,476,161 | No comparison | 1 | SEC filing |
| Feb 7, 2022 | Amendment | $3,288,702 | $0vs Jan 4, 2022 | 6 | SEC filing |
| Jan 4, 2022 | Initial | $3,288,702 | No comparison | 6 | SEC filing |
| Dec 18, 2020 | Initial | $198,309 | No comparison | 1 | SEC filing |
| Jun 23, 2020 | Initial | $113,371 | No comparison | 1 | SEC filing |
| Jun 22, 2018 | Initial | $1,541,783 | No comparison | 1 | SEC filing |
| Jun 6, 2018 | Initial | $852,219 | No comparison | 3 | SEC filing |
| Jul 31, 2017 | Initial | $245,558 | No comparison | 3 | SEC filing |
| Apr 14, 2016 | Initial | $370,435 | No comparison | 3 | SEC filing |
| Jul 22, 2014 | Initial | $5,971,000 | No comparison | 8 | SEC filing |
| Dec 28, 2012 | Initial | $6,303,211 | No comparison | 14 | SEC filing |
| Jun 23, 2011 | Initial | $5,273,385 | No comparison | 11 | SEC filing |
| Nov 26, 2010 | Initial | $1,354,526 | No comparison | 7 | SEC filing |
| Dec 31, 2009 | Initial | $100,808 | No comparison | 2 | SEC filing |
| Jul 23, 2009 | Initial | $172,080 | No comparison | 1 | SEC filing |
| Jan 14, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $228K
- Finders' fees
- $0
- Form D file number
- 021-437799
The additional $1,741,396.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. Dollar amounts are based on the Bank of Canada average rate of exchange reported on March 2, 2022, which wad Cdn$1.2668=USD$1.00.
Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable for one additional share until March 2, 2026 at Cdn$0.2206 per share.
Includes broker warrants to purchase 800,000 common shares of the issuer at Cdn$0.2206 per share for a period of 4 years.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Mar 17, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leslie Auld | Director, Executive |
| Floyd C. Dent Iii | Director |
| Heiner Dreismann | Director |
| Harry Glorikan | Director |
| Harry Glorikian | Director |
| James R. Howard Tripp | Director, Executive |
| Richard Janice Huston | Director |
| Gailina Liew | Director, Executive |
| Choon Chin Liew | Director, Executive |
| Garth Macrae | Director |
| Garth Mac Rae | Director |
| K Wayne Marshall | Director, Executive |
| Garth Mc Rae | Director |
| Rory Riggs | Director |
| David Sable | Director |
| Carl Solomon | Executive |
| Thomas Stewart Jr. | Director |
| Thomas D. Stewart, Jr. | Director |
| Fran Tuttle | Director |
| Karl Wassmann | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
70 East Beaver Creek Road Unit 30
Richmond Hill, A6, L4B 3B2
Richmond Hill, A6, L4B 3B2